Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France A study from the French Innovative Leukemia Organization (FILO) group.
Fiche publication
Date publication
mars 2017
Journal
American journal of hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre, Pr FORNECKER Luc-Matthieu, Pr DELMER Alain
Tous les auteurs :
Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L
Lien Pubmed
Mots clés
Aged, Aged, 80 and over, Antineoplastic Agents, administration & dosage, Cardiovascular Diseases, chemically induced, Dose-Response Relationship, Drug, Female, France, epidemiology, Gastrointestinal Diseases, chemically induced, Hematologic Diseases, chemically induced, Humans, Infection, etiology, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Male, Molecular Targeted Therapy, Protein Kinase Inhibitors, administration & dosage, Pyrazoles, administration & dosage, Pyrimidines, administration & dosage, Salvage Therapy, Treatment Outcome
Référence
Am. J. Hematol.. 2017 Mar;: